Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)

National Institutes of HealthUp to $1,500,000Due Nov 5, 2027

Researchers Schools & universities Government / tribal Nonprofits Large award Narrow eligibility

Deadline: Nov 5, 2027
Posted: Dec 4, 2024
Award amount: Up to $1,500,000
Focus areas: Health

Don’t miss this deadline

We’ll email you before Nov 5, 2027 so you have time to apply.

In plain English

This NIH/NIA U01 funds preclinical and early (Phase I) clinical development of new drug candidates that aim to prevent, slow, or treat Alzheimer's disease. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it targets research organizations, not individuals. Awards run up to about $1.5 million. Basic mechanism studies, repurposed drugs, and stand-alone clinical trials are out of scope, so the research focus is narrow.

AI-generated summary to help you decide quickly — verify the official eligibility rules before applying.

Who can apply

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

About this grant

The goal of this Notice of Funding Opportunity (NOFO) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry; pharmacokinetics (PK); Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET); efficacy in animal models; development of biomarkers for target engagement; formulation development; chemical synthesis under Good Manufacturing Practices (GMP); Investigational New Drug (IND) enabling studies; and initial Phase I clinical testing. Applications not responsive to this NOFO include research on basic mechanisms of disease or mechanisms of drug action; development ofrisk, diagnostic, prognostic, predictive, and preventionbiomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combination therapies; discovery activities such as high-throughput screening and hit optimization; and stand-alone clinical trials.

Let AI draft your application

Your first draft is free: a narrative and budget outline tailored to this grant, emailed to you. Drafts are written in a nightly batch, so it arrives by email later — not instantly on this page.

Application Kit — $49 one-time

Winner intelligence + a first-draft narrative grounded in applications that actually won. One payment, no subscription.

Get the Application Kit →

Related grants

Other open grants funding Health — soonest deadline first.

Also listed under National Institutes of Health and Health Grants.

Source: public records via Grants.gov. UseGrants is an independent aggregator, not affiliated with any funding agency. Always confirm details on the official listing before applying.